AL Amyloidosis Diagnostic Market is Driven by Increasing Prevalence of AL amyloidosis
The global amylosis diagnostic market is driven by increasing prevalence of AL amylosis across the globe. AL amylosis or light-chain (AL) amyloidosis is caused by abnormal light chains or amyloid fibrils from plasma cells that disrupt organ function. Amyloidosis diagnostic products include blood tests, imaging tests and biopsies that help diagnose AL amyloidosis.
Blood tests such as serum and urine protein electrophoresis and immunofixation electrophoresis are widely used to detect abnormal proteins produced by plasma cells causing AL amyloidosis in blood. Imaging tests like nuclear scans using radiopharmaceutical agents that bind to amyloid deposits help detect amyloidosis in organs. Tissue biopsy is the gold standard test to establish an amyloidosis diagnosis and determine amyloid type by examining a small sample of affected tissue under a microscope.
The AL amyloidosis diagnostic market is estimated to be valued at USD 1.068 billion in 2024 and is expected to reach USD 1.693 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
The growing demand for improved diagnostic techniques for amyloidosis owing to increasing prevalence of amyloidosis diseases like AL Amyloidosis Diagnostic Market is a major factor driving market growth.
Get more insights on: AL Amyloidosis Diagnostic Market
Get this Report in Japanese Language: ALアミロイドーシス診断市場
Get this Report in Korean Language: AL 아밀로이드증 진단 시장
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian